Twenty-four subjects (both male and female) were seen in a clinical office setting. The subjects suffered from acute injuries (under 30 days) sustained during the course of athletic endeavor.
The patient’s were selected on a random basis to receive either a placebo or Lignisul MSM (methylsulfonylmethane) in addition to routine chiropractic manipulation, ultrasound and muscle stimulation at each visit.
All patients were treated with similar therapy and all patients received unmarked capsules of either a placebo or Lignisul MSM. Patients were discharged from care once all their symptoms were resolved. Of the twelve patients who received placebo four of the twelve graded their results as excellent or good, while of the twelve patients on Lignisul MSM seven of the twelve graded their symptom reduction as excellent or good.
This represented a 58.3% of symptom reduction on Lignisul MSM, versus 33.3% on placebo. Of greater significance, however, was the fact that patients on Lignisul MSM had 3.25 visits on an average, while those on placebo had 5.25 visits. This means that patients on Lignisul MSM had 40% fewer visits to the office before reaching a recovery phase. This represents sizable economic advantage.
This paper discusses the chemical nature of MSM, the possible mechanisms involved in treatment of such sports injuries and the implications for future usage of this phytonutrient for the treatment of short term athletic injuries.
This premliminary simple study was performed to initially evaluate 16 patients suffering from degenerative arthritis as to the effect of using LIGNISULMSM™ to control their pain.
Eight patients, randomly chosen, were treated with 2250 mgms of M.S.M. per day. Six patients received placebo capsules. Results indicate a better than 80 percent control of pain within six weeks of beginning the study, while only two patients showed a minimal improvement (less than 20 percent) on the placebo.
Although this was only a simple preliminary study, it appears that a more intensive investigation of M.S.M. is warranted. A larger group of arthritic patients and an additional measurement evaluation (such as range of motion, etc.) should be utilized in such a future study. LIGNISULMSM™ may offer a significant new nutritional substance for the control of arthritic pain as a safe, non-toxic method.
A total of 21 patients were studied for 6 weeks for the hair study component. Data was collected by Certified Cosmetologists under the direction of the Principal Investigator.
Both the investigators and the patients were blinded as to whether supplementation was with placebo or LIGNISULMSM. The subjects were randomly assigned to either Group A (placebo) or Group B (LIGNISULMSM). Sixteen of the subjects were men and 5 were women. Dosage was 3,000 mg/day in both Groups A & B.
The study participants were studied for hair length, brilliance, and diameter of the individual hair fibers using industrystandard measurement scales at the beginning of the study period (t=0) and after 6 weeks (t=6 weeks).
Denna text får inte reproduceras, därför finns ingen abstract att tillgå. Klicka på länken ovan för att läsa hela studien.
